New Markers for Prostate Cancer Detection and Prognosis

Prostate cancer (PCa) is the most commonly diagnosed solid tumor among men in the United States and Europe. Even without treatment, PCa-specific mortality rates at 5 and 10 years remain low. Improvements in optimizing screening, diagnosis, and treatment have resulted in decreasing PCa mortality. Nevertheless, certain challenges still remain for men facing important disease state decisions and there is a need for biomarkers that can help.